Friday, July 10, 2026
← Back to archivePolicy
Policy•STAT News•Jul 9, 2026
Whistleblower takes on health insurance and FDA commissioner candidates
background ▾
- •A whistleblower has filed suit challenging potential contract violations by a health insurance contractor managing New Jersey state worker benefits, highlighting ongoing healthcare system dysfunction
Vertex PharmaceuticalsCrinetics PharmaceuticalsAstraZeneca
→ Read original articlePolicy•Fierce Biotech•Jul 10, 2026
ARPA-H awards up to $160M to scientists developing custom genetic medicines
background ▾
- •ARPA-H is institutionalizing the umbrella clinical trial model for personalized genetic medicines, requiring first-in-human trials by year three and signaling major U.S. government commitment to addressing the personalized therapy regulatory and access bottleneck for rare genetic diseases.
- •Children's Hospital of Philadelphia secured the largest award ($38.9M) and will lead efforts on four rare liver diseases, leveraging its success with baby KJ Muldoon's custom therapy and bringing together key researchers Ahrens-Nicklas, George, and Musunuru.
- •Watch for: regulatory pathway clarity from FDA on umbrella trial designs for personalized medicines; whether cost-reduction claims (Gemma/Profluent base-editing approach) materialize; and which of the six major projects reaches IND status first, potentially validating the accelerated timeline.
Children's Hospital of PhiladelphiaInnovative Genomics InstituteGemma Biotherapeutics
→ Read original articlePolicy•KFF•Jul 9, 2026
New KFF Poll Examines Patterns of Belief Across Common Vaccine Myths — The Monitor
background ▾
- •Only 1% of adults are consistent vaccine myth believers, while 55% are consistent or leaned myth deniers, indicating that firm vaccine skepticism is a marginal position in the U.S. population
- •31% of Americans fall into a "mixed middle" category expressing significant uncertainty about vaccine safety claims, representing a potentially more receptive audience for counter-misinformation campaigns than committed skeptics
MMR vaccinemeasles vaccineCOVID-19 vaccine
→ Read original articlePolicy•STAT News•Jul 10, 2026
New York boys club has a time-tested recipe to protect members’ mental health
background ▾
- •This is not pharma/biotech news—it is a general interest feature about a nonprofit youth organization and mental health epidemiology in adolescent males
Policy•STAT News•Jul 10, 2026
Opinion: The primary care crisis paradox
background ▾
- •MedPAC data contradicts the 'primary care crisis' narrative—Medicare beneficiaries have high PCP access and short wait times, yet policy continues to prioritize primary care reimbursement increases
- •The budget-neutral Medicare fee schedule forces a zero-sum game: primary care gains arithmetically require cuts to specialty care, and declining specialist access is now documented in CAHPS scores and patient surveys
- •Watch how policymakers respond to this data—whether Medicare payment reform will move beyond the primary care/specialty care tradeoff toward broader health system redesign addressing social determinants
Market Access
Market Access•Fierce Biotech•Jul 9, 2026
Illumina names new commercial, legal chiefs as sequencing business shows signs of stability
background ▾
- •Illumina is rebuilding its executive bench with experienced commercial and legal leaders after two years of regulatory crises, Grail divestiture, and China export restrictions
- •Q1 2025 results show stabilization with 4.8% revenue growth and raised full-year guidance, though China sales remain impacted by the Unreliable Entities List designation
- •Watch for execution of Illumina's commercial strategy under Sullivan's leadership and resolution of remaining China regulatory constraints, plus impact of the Tempus AI partnership on sequencing test adoption
IlluminaCaris Life SciencesRoche
→ Read original articleMarket Access•Endpoints News•Jul 9, 2026
Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing down
background ▾
- •Eli Lilly's acquisition dominance in H1 biotech M&A demonstrates aggressive capital deployment strategy driven by strong financial position and obesity market success
- •Pattern of continued acquisition activity signals sustained M&A momentum and Lilly's commitment to inorganic growth
- •Watch for: identities of acquisition targets, acquisition values, and therapeutic area focus; impact on Lilly's R&D productivity and pipeline efficiency
Eli Lilly
→ Read original articleMarket Access•Endpoints News•Jul 9, 2026
UK price watchdog recommends against Amgen's Lumakras in lung cancer
background ▾
- •NICE negative recommendation for Lumakras blocks NHS funding for new patients in the UK, a critical market for early-stage lung cancer treatment
- •The rejection signals ongoing payer resistance to Lumakras's price point relative to demonstrated clinical benefit, impacting commercial viability in Europe
- •Amgen may pursue appeals or price negotiations with NICE, but outcome remains uncertain given the watchdog's explicit recommendation against coverage
AmgenLumakras (sotorasib)
→ Read original articleMarket Access•Endpoints News•Jul 9, 2026
Catalent to divest UK site; Rottendorf, Evonik announce manufacturing builds
background ▾
- •Catalent divesting UK site to Codis signals portfolio rationalization within the CDMO market
- •Rottendorf and Evonik manufacturing expansions indicate continued demand for outsourced production capacity
CatalentCodisRottendorf
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 9, 2026
Roche ends 2 Huntington’s disease programs, including Ionis-partnered tominersen
background ▾
- •Tominersen failed its phase 2 efficacy endpoint (GENERATION HD2) despite biomarker and safety success—the drug reduced mutant protein but did not improve clinical disease severity over 16 months, marking the second major clinical failure for this once-promising asset after its phase 3 collapse.
- •RG6496 discontinuation was driven by animal study data revealing the drug cannot be safely given chronically with repeated doses, halting the trial after enrollment of only three patients and signaling potential mechanism-of-action or safety liabilities in ASO development for Huntington's disease.
- •Watch for uniQure's AMT-130 gene therapy filing in Q3 2024 and any FDA decision, as it aims to become the first approved disease-modifying Huntington's treatment; monitor Roche's RG6662 gene therapy phase data and outcomes from competing programs in this high-unmet-need indication.
RocheIonisuniQuretominersenRG6496RG6662
→ Read original articleClinical Trials•Fierce Biotech•Jul 9, 2026
Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease
background ▾
- •FT819 showed clinical response in 4/4 treatment-resistant systemic sclerosis patients (improved modified Rodnan skin score) within 3 months with no CRS, ICANS, or GvHD, and minimal immunodepletion requirement—a notable safety and tolerability advantage over autologous CAR-T approaches.
- •Off-the-shelf allogeneic CAR-T cell therapy platform demonstrates reproducibility and scalability advantages; TRAC knockout design engineered to eliminate GvHD risk addresses major barrier to allogeneic cell therapy.
- •Watch for phase 1 basket trial expansion, durability data at 6-12 months, and regulatory pathway clarity for systemic sclerosis indication; systemic sclerosis remains unmet medical need with no disease-modifying monotherapy approved despite affecting 670K patients globally.
Fate TherapeuticsBoehringer IngelheimGenentechFT819OfevActemra
→ Read original articleClinical Trials•Endpoints News•Jul 9, 2026
Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront
background ▾
- •Ipsen's Dysport successfully met primary endpoints in Phase 3 migraine trials, potentially opening a new therapeutic indication for the established neurotoxin platform
- •Tarsus Pharmaceuticals acquired iRenix for $75 million upfront, signaling continued portfolio expansion and M&A activity in the sector
- •Monitor regulatory pathway and timeline for Dysport migraine NDA/BLA filing and iRenix program details
IpsenTarsus PharmaceuticalsiRenixDysportabobotulinumtoxinA
→ Read original articleClinical Trials•Fierce Biotech•Jul 9, 2026
GSK cuts losses on $700M upfront Alzheimer’s collab with Alector following 2 clinical failures
background ▾
- •Both GSK-Alector sortilin inhibitors failed clinical development (latozinemab in FTD phase 3; nivisnebart in AD phase 2), invalidating the progranulin-boosting strategy and costing GSK $700M in upfront fees
- •The termination reflects a strategic pivot under new CEO Luke Miels toward compounds that improve on existing treatments rather than unproven mechanisms
- •Watch for Alector's blood-brain barrier technology platform (planned anti-amyloid antibody IND filing Q1 2025) and GSK's Jackson Laboratory partnership results as alternative neurodegenerative approaches mature
GSKAlectorThe Jackson Laboratorylatozinemabnivisnebart
→ Read original article